Abbott Laboratories (ABT) Stock Analysis
Healthcare · Medical Devices
Hold if already holding. Not a fresh buy at $87.80, but acceptable to hold if already in. Reasons: Weak growth; Negative momentum.
Abbott Laboratories discovers, manufactures, and sells a diversified line of healthcare products across Established Pharmaceuticals, Diagnostics, Nutritionals, and Medical Devices segments to 160+ countries, employing approximately 115,000. Sales outside the U.S. represented... Read more
Hold if already holding. Not a fresh buy at $87.80, but acceptable to hold if already in. Reasons: Weak growth; Negative momentum. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Maintain position. Not compelling to add more. Score 5.2/10, moderate confidence.
Passes 7/9 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 58d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA). Suitability: moderate.
Recent Developments — Abbott Laboratories
Latest news
- Abbott Laboratories Boosts Dividend, Stock Recovers from Mid-Year Pullback (NYSE:ABT) - Stock Investor — Stock Investor positive
- Abbott Laboratories (ABT) Set for Q1 Earnings Report with Modest Growth Expectations - GuruFocus — GuruFocus neutral
- Abbott Laboratories Insiders Added US$3.10m Of Stock To Their Holdings - Yahoo Finance — Yahoo Finance positive
- Is Abbott (ABT) the Best Oversold Blue Chip Stock to Buy? - Yahoo Finance — Yahoo Finance positive
- Abbott (ABT) stock rated buy on strong diabetes trial results - MSN — MSN positive
Generated 2026-05-20T21:06:21Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
2 floor-breakers
Growth below the gate floor. Component breakdown shows what dragged the score down.static
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $87.80, but acceptable to hold if already in. Reasons: Weak growth; Negative momentum. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Maintain position. Not compelling to add more. Target $106.78 (+21.6%), stop $83.55 (−5.1%), A.R:R 3.2:1. Score 5.2/10, moderate confidence.
Take-profit target: $106.78 (+21.5% upside). Target $106.78 (+21.6%), stop $83.55 (−5.1%), A.R:R 3.2:1. Stop-loss: $83.55.
Weak growth; Negative momentum; Below 200-MA, MA slope -4.5%/30d (confirmed downtrend).
Abbott Laboratories trades at a P/E of 23.7 (forward 13.9). TrendMatrix value score: 6.6/10. Verdict: Hold.
35 analysts cover ABT with a consensus score of 4.0/5. Average price target: $119.
What does Abbott Laboratories do?Abbott Laboratories discovers, manufactures, and sells a diversified line of healthcare products across Established...
Abbott Laboratories discovers, manufactures, and sells a diversified line of healthcare products across Established Pharmaceuticals, Diagnostics, Nutritionals, and Medical Devices segments to 160+ countries, employing approximately 115,000. Sales outside the U.S. represented approximately 61% of net sales in 2025, with no single customer posing a material loss risk.